Nisa Investment Advisors’s Neurocrine Biosciences NBIX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $228K | Sell |
1,729
-3,472
| -67% | -$461K | ﹤0.01% | 1172 |
|
|
2025
Q4 | $738K | Sell |
5,201
-21,945
| -81% | -$3.18M | ﹤0.01% | 903 |
|
|
2025
Q3 | $3.81M | Buy |
27,146
+13,878
| +105% | +$1.88M | 0.01% | 470 |
|
|
2025
Q2 | $1.67M | Sell |
13,268
-774
| -6% | -$88.8K | 0.01% | 683 |
|
|
2025
Q1 | $1.55M | Buy |
14,042
+12,767
| +1,001% | +$1.62M | 0.01% | 710 |
|
|
2024
Q4 | $174K | Sell |
1,275
-70
| -5% | -$8.66K | ﹤0.01% | 1332 |
|
|
2024
Q3 | $155K | Sell |
1,345
-5,662
| -81% | -$776K | ﹤0.01% | 1337 |
|
|
2024
Q2 | $965K | Sell |
7,007
-208
| -3% | -$28.5K | 0.01% | 889 |
|
|
2024
Q1 | $995K | Sell |
7,215
-18,389
| -72% | -$2.51M | 0.01% | 881 |
|
|
2023
Q4 | $3.37M | Buy |
25,604
+4,687
| +22% | +$540K | 0.02% | 512 |
|
|
2023
Q3 | $2.35M | Sell |
20,917
-3,980
| -16% | -$419K | 0.02% | 621 |
|
|
2023
Q2 | $2.35M | Sell |
24,897
-246
| -1% | -$24K | 0.02% | 638 |
|
|
2023
Q1 | $2.54M | Buy |
25,143
+6,772
| +37% | +$705K | 0.02% | 603 |
|
|
2022
Q4 | $2.19M | Buy |
18,371
+17,546
| +2,127% | +$2.06M | 0.02% | 707 |
|
|
2022
Q3 | $88K | Sell |
825
-77
| -9% | -$7.81K | ﹤0.01% | 1547 |
|
|
2022
Q2 | $88K | Hold |
902
| – | – | ﹤0.01% | 1545 |
|
|
2022
Q1 | $85K | Sell |
902
-30,852
| -97% | -$2.61M | ﹤0.01% | 1679 |
|
|
2021
Q4 | $2.51M | Buy |
31,754
+27,668
| +677% | +$2.55M | 0.02% | 585 |
|
|
2021
Q3 | $392 | Sell |
4,086
-1,237
| -23% | -$117K | ﹤0.01% | 1191 |
|
|
2021
Q2 | $518 | Hold |
5,323
| – | – | ﹤0.01% | 1134 |
|
|
2021
Q1 | $518 | Sell |
5,323
-1,050
| -16% | -$110K | ﹤0.01% | 1162 |
|
|
2020
Q4 | $611K | Buy |
6,373
+1,830
| +40% | +$177K | ﹤0.01% | 1098 |
|
|
2020
Q3 | $437K | Sell |
4,543
-3,293
| -42% | -$381K | ﹤0.01% | 1083 |
|
|
2020
Q2 | $956K | Sell |
7,836
-14,860
| -65% | -$1.64M | 0.01% | 804 |
|
|
2020
Q1 | $1.96M | Buy |
22,696
+2,852
| +14% | +$279K | 0.02% | 538 |
|
|
2019
Q4 | $2.13M | Buy |
19,844
+13,579
| +217% | +$1.42M | 0.02% | 620 |
|
|
2019
Q3 | $565K | Buy |
6,265
+135
| +2% | +$12.6K | 0.01% | 1054 |
|
|
2019
Q2 | $518K | Buy |
6,130
+165
| +3% | +$13.5K | ﹤0.01% | 1065 |
|
|
2019
Q1 | $526K | Buy |
5,965
+358
| +6% | +$29.9K | 0.01% | 1044 |
|
|
2018
Q4 | $400K | Sell |
5,607
-13,984
| -71% | -$1.34M | ﹤0.01% | 1063 |
|
|
2018
Q3 | $2.41M | Buy |
19,591
+19,091
| +3,818% | +$2.17M | 0.02% | 586 |
|
|
2018
Q2 | $49K | Buy |
500
+100
| +25% | +$8.95K | ﹤0.01% | 1455 |
|
|
2018
Q1 | $34K | Buy |
+400
| New | +$33.8K | ﹤0.01% | 1455 |
|
|
2016
Q4 | – | Sell |
-1,000
| Closed | -$51K | – | 1885 |
|
|
2016
Q3 | $51K | Hold |
1,000
| – | – | ﹤0.01% | 1401 |
|
|
2016
Q2 | $45K | Hold |
1,000
| – | – | ﹤0.01% | 1407 |
|
|
2016
Q1 | $40K | Buy |
+1,000
| New | +$39.7K | ﹤0.01% | 1422 |
|
Other funds holding NBIX
VPM
VCM
Nisa Investment Advisors's NBIX Position: Q1 2026 in Review
Nisa Investment Advisors reduced its Neurocrine Biosciences (NBIX) stake by 67% in Q1 2026, selling an estimated $461K and leaving 1,729 shares worth $228K. The position accounts for ﹤0.01% of the portfolio, ranked #1172.
Nisa Investment Advisors first reported a position in NBIX in Q1 2016 and has held it in 36 quarters since. The position peaked at $3.81M in Q3 2025. 696 funds tracked by Wall St. Rank hold NBIX as of Q1 2026.
- Nisa Investment Advisors held 1,729 shares of Neurocrine Biosciences worth $228K as of Q1 2026.
- Nisa Investment Advisors sold 3,472 Neurocrine Biosciences shares in Q1 2026, an estimated $461K.
- Neurocrine Biosciences made up ﹤0.01% of Nisa Investment Advisors's portfolio in Q1 2026, its #1172 holding.
- Nisa Investment Advisors first reported a position in Neurocrine Biosciences in Q1 2016 and has held it in 36 quarters since.
- Nisa Investment Advisors's Neurocrine Biosciences position peaked at $3.81M in Q3 2025.
- 696 funds tracked by Wall St. Rank held Neurocrine Biosciences as of Q1 2026.
Based on Nisa Investment Advisors's 13F filing for Q1 2026, filed 30 Apr 2026.